Future Horizons in Lung Cancer 2016

Prof Gordon McVie (Kings College London, London, UK) chairs an expert discussion for ecancertv at the Future Horizons in Lung Cancer in London with Prof Caroline Dive (Cancer Research UK Manchester Institute, Manchester, UK), Dr Marianne Nicolson (Aberdeen Royal Infirmary, Aberdeen, UK) and Prof Michael Seckl (Imperial College London, London, UK) The panel discuss the key topics to come out of this important meeting, covering the recent advances and emerging therapies in lung cancer. They cover multi disciplinary approaches, targeted therapies and the future potential of personalised medicine when treating patients within this therapeutic area. The panel also discuss the potential and advances of new technologies which are able to diagnose patients, without invasive treatments through advances in imaging. Other topics include novel PET tracers, omics and screening databases, fluid biopsies, checkpoint inhibitors, EGFR drugs and the ALK gene.

Prof Fennell talks to ecancertv at the Future Horizons In Lung Cancer conference about immunotherapy in small cell lung cancer (SCLC), and the treatment advances in the last decade for this relatively rare disease.

Dr Pardo talks to ecancertv at the Future Horizons In Lung Cancer conference about metabolomic analysis as a new way to find pathways that can be targeted in cancer to reverse drug resistance.

Prof Field talks to ecancertv at the Future Horizons In Lung Cancer conference about lung cancer screening programmes in the UK. He also discusses the mortality of lung cancer, CT screening and the Liverpool Healthy Lung Project.

Dr McGranahan talks to ecancertv at the Future Horizons In Lung Cancer conference about tumour heterogeneity and the impact on patient care in Non-small cell lung cancer (NSCLC).

Dr Rosell talks to ecancertv at the Future Horizons In Lung Cancer conference about understanding the mechanisms of immunotherapy and how it has changed the process of treatment. Immunotherapy can be of substantial benefit to the patient, due to it's ability to shrink lung cancer tumours.

Prof Dive talks to ecancertv at the Future Horizons In Lung Cancer conference about developing new models in Small-cell lung cancer (SCLC). She also discusses drug resistance and the steps being taken to improve outcomes for patients.

Prof Ng talks to ecancertv at the Future Horizons In Lung Cancer conference about the future of imaging in lung cancer and the need to develop newer imaging agents that are matched to drugs, and solutions that are economically viable. He also discusses the need to combine blood tests and imaging to detect cancer.

Dr O'Brien talks to ecancertv at the Future Horizons In Lung Cancer conference about her stance on PDL1 and other biomarkers for selecting patients for immune checkpoint therapies. She argues that testing for markers has brought improvements in patient selection for treatments, benefited survival and is an affordable option.

Prof Faivre-Finn talks to ecancertv at the Future Horizons In Lung Cancer conference about current state of the art radiotherapy in lung cancer. In the last decade, advanced radiotherapy techniques have translated into improvement in local control and survival.

Dr Henschke talks to ecancertv at the Future Horizons In Lung Cancer conference about CT screening for lung cancer, with a focus on avoiding false positives.

Dr Landau talks to ecancertv at the Future Horizons In Lung Cancer conference about future directions in radiation medicine in early stage lung cancer. He also discusses patient issues regarding survivorships and outcomes in surgery and radiotherapy.

Dr Di Meco talks to ecancertv at the Future Horizons In Lung Cancer conference about future smart surgical approaches for brain metastases. He focuses on some of the open questions in brain metastases, such as issues regarding surgery and radiotherapy.

Dr Besse talks to ecancertv at the Future Horizons In Lung Cancer conference about his stance on maintenance in Non-small cell lung cancer (NSCLC). Several studies have assessed the benefit of maintenance therapy following platinum-based first-line therapy, to improve disease control, and thus, progression-free and overall survival with minimal toxicity and maintenance or improvement of quality of life of patients.

Dr Veronesi talks to ecancertv at the Future Horizons In Lung Cancer conference about the surgical improvements and management in lung cancer, and the advancement in imaging.